

DAFTAR PUSTAKA

- Abbate, M., Zoja, C. & Remuzzi, G., 2006. How does proteinuria cause progressive renal damage?. **J. Am. Soc. Nephrol.**, 17(11), pp. 2974-2984.
- Ackland, P., 2013. Prevalence, Detection, Evaluation and Management of Chronic Kidney Disease. In: D. Goldsmith, S. Jayawardene & P. Ackland (Eds.). **ABC of Kidney Disease**. West Sussex: John Wiley & Sons, pp. 15-22.
- Bargman, J. M. & Skorecki, K., 2015. Chronic Kidney Disease. In: D. L. Kasper, et al., (Eds.). **Harrison's Principles of Internal Medicine**. Ed. 19th, New York: McGraw Hill, pp 1811-1815.
- Barrett, K. E., Barman, S. M., Scott, B. & Brooks, H. L., 2012. Renal Physiology. In: **Ganong's Review of Medical Physiology**, Ed 24th, New York: McGraw Hill Medical, p. 674.
- CHMP, 2005. **Guideline on the Core SPC for Human Albumin Solution**. London: EMEA.
- Cipolle, R. J., Strand, L. M. & Morley, P. C., 2012. **Pharmaceutical Care Practice: The Patient-Centered Approach to Medication Management Services**, Ed 3rd, New York: McGraw-Hill Education, pp. 100-133
- Cohen, S. D. & Kimmel, P. L., 2007. Nutritional Status, Psychological Issues and Survival in Hemodialysis Patients. **Contrib. Nephrol.**, Volume 155, pp. 1-17.
- Corbett, A. H. et al., 2015. **Drug Information Handbook**. 23rd Edition. Ohio: Lexicomp, pp-87-89.
- Curhan, G. C., 2015. Nephrolithiasis. In: D. L. Kasper, et al. (Eds.). **Harrison's Principles of Internal Medicine**. Ed. 19th, New York: McGraw Hill, pp 1866-1869.

- Dobre, M. A., Meyer, T. W. & Hostetter, T. H., 2015. The Uremic Syndrome. In: P. L. Kimmel & M. E. Rosenberg, (Eds). **Chronic Renal Disease**. Amsterdam: Academic Press, p. 85.
- Fischbach, F. & Dunning, M. B., 2015. **A Manual of Laboratory and Diagnostic Tests**. Ed 9th, Philadelphia: Wolters Kluwer Health.
- Franch-Arcas, G., 2001. The Meaning of Hypoalbuminemia in Clinical Practice. **Clin. Nutr.**, 20(3), pp. 265-269.
- Friden, V. et al., 2011. The Glomerular Endothelial Cell Coat is Essential for Glomerular Filtration. **Kidney Int.**, 79(12), pp. 1322-30.
- Friedman, P. A., 2011. Agents Affecting Mineral Ion Homeostasis and Bone Turnover. In: L. L. Brunton, B. A. Chabner & B. C. Knollmann, (Eds.). **Goodman & Gilman's The Pharmacological Basis of Therapeutics**. New York: McGraw-Hill, pp. 1289-1292.
- Gales, B. J. & Erstad, B. L., 1993. Adverse Reactions to Human Serum Albumin. **Ann. Pharmacother.**, 27(1), pp. 87-89.
- Garg, A. X. et al., 2001. Association Between Renal Insufficiency and Malnutrition in Older Adults: Result from The NHANES III. **Kidney Int.**, 60(5), pp. 1867-1874.
- Gatta, A., Verardo, A. & Bolognesi, M., 2012. Hypoalbuminemia. **Intern. Emerg. Med.**, 7(3), pp. 193-199.
- Glasscock, R. J. & Rule, A. D., 2012. The Implications of Anatomical and Functional Changes of the Aging Kidney: With an Emphasis on the Glomeruli. **Kidney Int.**, 82(3), pp. 270-7.
- Grossman, S., 2014. Disorder of Fluid and Electrolyte Balance. In: S. Grossman & C. M. Porth, (Eds.). **Porth's Pathophysiology Concepts of Altered Health States**. Philadelphia: Wolters Kluwer, pp. 1027-1029.
- Hahn, G. R., 2011. Colloid Fluids. In: G. R. Hahn, (Ed.). **Critical Fluid Therapy in The Perioperative Setting**. New York: Cambridge University Press, pp. 11-16.

- Haller, C., 2006. Hypoalbuminemia in Renal Failure: Pathogenesis and Therapeutic Consideration. **Kidney Blood Pres. Res.**, 28(1), pp. 307-310.
- Hall, J. E., 2010. **Guyton and Hall: Textbook of Medical Physiology**. Ed. 12th. New York: Saunders.
- Herrmann, F. R., Safran, C., Levkoff, S. E. & Minaker, K. L., 1992. Serum Albumin Level on Admission as a Predictor of Death, Length of Stay, and Readmission. **Arch. Intern. Med.**, 152(1), pp. 125-130.
- Hospital Transfusion Committee, 2010. **Human Albumin Solution Infusion - Guideline for Practice**. s.l.: Peterborough and Stamford Hospitals.
- Hoyert, D. L. & Xu, J., 2012. Deaths: Preliminary Data for 2011. **National Vital Statistics Report**, 61(6).
- Hudson, J. Q. & Wazny, L. D., 2014. Chronic Kidney Disease. In: J. T. Dipiro, ed. **Pharmacotherapy and Patophysiology Approach**, Ed. 9th. New York: McGraw Hill, pp. 633-670.
- Join Formulary Committee, 2015. **British National Formulary**. Ed. 69th. London: Pharmaceutical Press, p. 656.
- K/DOQI, 2002. Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation Classification and Stratification. **Am. J. Kidney Dis.**, 39(1), pp. 1-266.
- Kashani , A., Landaverde, C., Medici, V. & Rossaro, L., 2008. Fluid Retention in Cirrhosis: Pathophysiology and Managment. **Q. J. Med.**, Volume 101, pp. 71-85.
- Kaysen, G. A., 1996. Hypoalbuminemia in Dialysis Patients. **Seminar in Dialysis**, 9(3), pp. 249-256.
- KDIGO CKD Work Group, 2013. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kideny Disease. **Kidney Int.**, 3(1), pp. 1-150.
- Keddis, M. T. & Rule, A. D., 2013. Nephrolithiasis and Loss of Kidney Function. **Curr. Opin. Nephrol. Hypertens.**, 22(4), pp. 390-396.

- Kemenkes RI, 2013a. **Riset Kesehatan Dasar**, Jakarta: Kementrian Kesehatan RI.
- Kemenkes RI, 2013b. **Farmakoepi Indonesia Edisi V**. Jakarta: Kementrian Kesehatan RI. pp 65-66
- Kemenkes RI, 2011a. **Pedoman Visite**. Jakarta : Kementrian Kesehatan RI.
- Kemenkes RI, 2011b. **Pedoman Interpretasi Data Klinik**. Jakarta: Kementrian Kesehatan RI.
- Keputusan Menteri Kesehatan Republik Indonesia Nomor 159 tahun 2014 tentang Perubahan atas KMK Nomor 328 tahun 2013 tentang Formularium Nasional. 2014. Jakarta.
- Keputusan Direktur Jenderal Bina Kefarmasian dan Alat Kesehatan Nomor HK.02.03/III/1346/2014 tentang Pedoman Penerapan Formularium Nasional. 2014. Jakarta.
- Khoury, C. C., Chen, S. & Ziyadeh, F. N., 2015. Pathophysiology of Diabetic Nephropathy. In: P. L. Kimmel & M. E. Rosenberg, (Eds.). **Chronic Renal Disease**. Amsterdam: Academic Press, pp. 151-153.
- Komite Medik Terapi, 2003. **Pedoman Penggunaan Albumin**. Surabaya: RS Dr. Soetomo.
- Lacy, C. F. et al., 2009. **Drug Information Handbook**, 17th Edition. Ohio: Lexicomp.
- Liu, K. D. & Chertow, G. M., 2015. Dialysis in the Treatment of Renal Failure. In: D. L. Kasper, et al. (Eds.). **Harrison's Principles of Internal Medicine**. Ed. 19th, New York: McGraw Hill, pp 1822-1823.
- Liumbruno, G. et al., 2009. Recommendation for the Use of Albumin and Immunoglobulins. **Blood Transfusion**, 7(3), pp. 216-234.
- López-Novoa, J. M., Martínez-Salgado, C., Rodríguez-Peña, A. B. & López Hernández, F. J., 2010. Common pathophysiological mechanisms of chronic kidney disease: Therapeutic perspectives. **Pharmacol. Therapeut.**, 128(1), pp. 61-81.

- Margarson, M. P. & Soni, N. C., 2004. Changes in Serum Albumin Concentration and Volume Expanding Effects Following a Bolus of Albumin 20% in Septic Patients. **Brit. J. Anaesth.**, 92(6), pp. 821-826.
- McEvoy, G. M. et al., 2011. **AHFS Drug Information Essentials**. Bethesda: American Society of Health-System Pharmacists.
- Naranjo et al., 1981. A method for estimating the probability of adverse drug reactions. **Clin. Pharmacol. Ther.**, 30(2), pp 239-245.
- Nasrallah, M. M. et al., 2012. Endogenous Soluble Receptor of Advanced Glycation End-products (esRAGE) is Negatively Associated with Vascular Calcification in Non-diabetic Hemodialysis Patients. **Int. Urol. Nephrol.**, 44(4), pp. 1193-9.
- National Kidney Foundation, 2005. K/DOQI Clinical Practice Guidelines for Cardiovascular Disease in Dialysis Patients. **Am. J. Kidney Dis.**, 45(4), pp. S1-S154.
- Neugarten, J. & Reckelhoff, J. F., 2015. Gender Issues in Chronic Kidney Disease. In: P. L. Kimmel & M. E. Rosenberg, (Eds.). **Chronic Renal Disease**. Amsterdam: Academic Press, pp. 69-72.
- Nicholson, J. P., Wolmarans, M. R. & Park, G. R., 2000. The Role of Albumin in Critical Illness. **Brit. J. Anaesth.**, 85(4), pp. 599-610.
- NPPEAG, 2009. **Clinical Guidelines for Human Albumin Use**. NHS Scotland.
- O'Callaghan, C. A., 2009. **The Renal System at a Glance**. 3rd ed. West Sussex: Wiley Blackwell.
- Pagana, K. D. & Pagana, T. J., 2015. **Mosby's Diagnostic and Laboratory Test Reference**. 12th ed. St. Louis: Elsevier Mosby.
- Palmer, B. F., Alpern, R. J. & Seldin, D. W., 2013. Pathophysiology of Sodium Retention and Wastage. In: R. J. Alpern, O. W. Moe & M. Caplan, (Eds.). **Seldin and Giebisch's The Kidney Physiology and Pathophysiology**. Amsterdam: Academic Press, pp. 1283-1290.
- Perlman, R. L., Heung, M. & Ix, J. H., 2014. Renal Disease. In: G. D. Hammer & S. J. McPhee, (Eds.). **Pathophysiology of Disease: An**

- Introduction to Clinical Medicine**, Ed 7th. New York: McGraw-Hill, pp. 455-481.
- Peters, T., 1995. **All About Albumin - Biochemistry, Genetics, and Medical Applications**. New York: Academic Press.
- Planas, R. et al., 2006. Natural History of Patients Hospitalized for Management of Cirrhotic. **Clin. Gastroenterol. H.**, 4(11).
- Prakash, S. & O'Hare, A. M., 2009. Interaction of Aging and Chronic Kidney Disease. **Semin. Nephrol.**, 29(5), pp. 497-503.
- Rabelink, T. J., Heerspink, H. J. L. & Zeeuw, D. D., 2015. The Pathophysiology of Proteinuria. In: P. L. Kimmel & M. E. Rosenberg, (Eds.). **Chronic Renal Disease**. Amsterdam: Academic Press, pp. 92-93.
- Remuzzi, G., Benigni, A. & Remuzzi, A., 2006. Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes. **J. Clin. Invest.**, 116(2), pp. 288-296.
- Rennke, H. G. & Denker, B. M., 2014. **Renal Pathophysiology : The Essentials**. Ed. 4th. Philadelphia: Lippincott Williams & Wilkins.
- Sachdeva, P. D. & Patel, B. G., 2010. Drug Utilization Studies - Scope and Future Perspectives. **International Journal in Pharmaceutical and Biological Research**, 1(1), pp. 11-17.
- Schalanger, L. E., Bailey, J. L. & Sands, J. M., 2015. Aging and the Kidney: Clinical and Pathophysiological Issues. In: P. L. Kimmel & M. E. Rosenberg (Eds). **Chronic Renal Disease**. Amsterdam: Academic Press, pp. 126-133.
- Shargel, L., Wu-Pong, S. & Yu, A. B., 2004. **Applied Biopharmaceutics and Pharmacokinetics**. New York: McGraw Hill.
- Soni, N., 2009. Human Albumin Solutions and the Controversy of Crystalloids Versus Colloid. In: M. Contreras, (Ed). **ABC of Tranfusions**. West Sussex: Wiley Blackwell, pp. 48-53.
- Sweetman, S. C., 2009. **Martindale The Complete Drug Reference**. Edition 36th. London: Pharmaceutical Press.

- Trissel, L. A., 2009. **Handbook on Injectable Drugs**. Edition 15th. Bethesda: American Society of Health-System.
- UHC, 2010. **Guidelines for Use of Albumin**. s.l.:University Hospital Consortium.
- Weinbaum, S., Tarbell, J. M. & Damiano, E. R., 2007. The Structure and Function of the Endothelial Glycocalyx Layer. **Annu. Rev. Biomed. Eng.**, Volume 9, pp. 121-167.
- WHO, 2003. **Introduction to Drug Utilization Research**. Geneva: WHO.
- Wing, M. R., Raj, D. S. & Velasquez, M. T., 2015. Protein Energy Metabolism in Chronic Kidney Disease. In: P. L. Kimmel & M. E. Rosenberg, (Eds). **Chronic Renal Disease**. Amsterdam: Academic Press, pp. 106-125.
- Yeun, J. Y. & Kaysen, G. A., 1998. Factors Influencing Serum Albumin in Dialysis Patients. **Am. J. Kidney Dis.**, 32(6), pp. 118-125.
- Yokoyama, H. et al., 2009. Prevalence of Albuminuria and Renal Insufficiency and Associated Clinical Factors in Type 2 Diabetes: The Japan Diabetes Clinical Data Management Study. **Nephrol. Dial. Transplant.**, 24(1), pp. 1212-1219.
- Zhou, T., Lu, S., Zhang, Y. & Xu, F., 2013. Review of the rational use and adverse reactions to human serum albumin in the People's Republic of China. **Patient Prefer Adherence**, pp. 1207-1212.